MyD88 homodimerization inhibitors

Details for Australian Patent Application No. 2005318226 (hide)

Owner Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

Inventors Ruggiero, Vito; Mastroianni, Domenico; Carminati, Paolo; Sassano, Marica; Gallo, Grazia; Fanto', Nicola

Agent Davies Collison Cave

Pub. Number AU-A-2005318226

PCT Pub. Number WO2006/067091

Priority 04425929.9 20.12.04 EP

Filing date 16 December 2005

Wipo publication date 29 June 2006

International Classifications

C07K 14/705 (2006.01) Peptides having more than 20 amino acids

A61K 38/04 (2006.01) Medicinal preparations containing peptides - Peptides having up to 20 amino acids in a fully defined sequence

C07K 5/02 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/078 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 7/02 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 14/715 (2006.01) Peptides having more than 20 amino acids

Event Publications

12 July 2007 PCT application entered the National Phase

  PCT publication WO2006/067091 Priority application(s): WO2006/067091

14 July 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005318227-Stereoselective process and crystalline forms of a camptothecin

2005318225-Novel naphthyl substituted azabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors